Melanotan-2: Side Effects

Safety Notice#

The safety profile of Melanotan-2 in humans has not been established through controlled clinical trials. The information below is derived primarily from animal studies and should be interpreted accordingly.

Documented Adverse Effects#

Key details by context are summarized here:

• Animal studies and reviews. Central (paraventricular/ICV) and peripheral administration of MT‑II and other melanocortins in rodents and other species reliably evokes a behavioral syndrome (excessive grooming, yawning, stretching) and autonomic effects. Intravenous γ‑MSH–like peptides and MT‑II increase mean arterial pressure and heart rate transiently; dorsal vagal complex injections can elicit hypotension/bradycardia, consistent with site‑specific autonomic actions. These effects are reported qualitatively and repeatedly rather than with formal frequency denominators; duration is typically short‑lived in experimental paradigms. Reviews of brain melanocortin actions similarly emphasize grooming crises and related behavioral phenomena as canonical effects of MT‑II/a‑MSH agonism.

• Human case reports/series. A published case describes acute ischemic priapism following a 2 mg SC MT‑II “tanning” dose, requiring aspiration/irrigation, intracavernosal phenylephrine, and penoscrotal decompression, with subsequent erectile dysfunction and corporal fibrosis; the authors note only a few prior published instances, indicating rarity but high severity when it occurs. The same report also references systemic MT‑II toxicity with sympathomimetic features, renal dysfunction, and rhabdomyolysis in an earlier case. A systematic review of injecting IPEDs collates user‑reported reactions to MT‑II—nausea, flushing, headache, fatigue, dizziness, pigmentation changes—largely without denominators; these appear common among users but the evidence base is low‑quality.

• Frequencies and severity. Direct MT‑II human AE frequencies are not well quantified in the captured sources; most reports are case‑based. For context, the related MC4R agonist bremelanotide in controlled trials showed nausea 40% (with antiemetic use and 8% discontinuation due to nausea), flushing 20.3%, injection‑site reactions 13.2%, headache 11.3%, vomiting 4.8%, and transient blood‑pressure increases; these effects likely reflect on‑target melanocortin agonism and align with case‑based MT‑II observations, although MT‑II’s exact rates remain undetermined.

Limitations. The available evidence for MT‑II human side‑effect frequencies is limited to case reports/series and reviews of illicit use; standardized dosing, purity, and denominators are lacking. Animal data are robust for phenomena and mechanisms but seldom quantify frequency in a way directly transferable to humans.

Implications. Clinicians should anticipate centrally mediated nausea/vegetative symptoms, flushing, and pigmentation changes with MT‑II exposure; monitor for transient blood‑pressure increases; and recognize rare but serious risks such as ischemic priapism and systemic toxicity (including rhabdomyolysis) reported from non‑medical use."}

Human Safety Reports#

Known/strongly supported contraindications and cautions

• Uncontrolled hypertension or significant cardiovascular disease: Avoid/contraindicated. Melanocortin agonism (MC3R/MC4R) acutely increases blood pressure and alters heart rate; bremelanotide labeling and reviews specify contraindication in uncontrolled hypertension or cardiovascular disease, and animal/experimental data show MT‑II raises MAP/HR via MC3/4 with sympathetic involvement (including β1‑adrenergic contribution).
• History or risk of priapism: Avoid and monitor. MT‑II has case reports of ischemic priapism; the pro‑erectile effect is mediated primarily by MC4R within the CNS.
• Severe renal impairment: Use caution/avoid. Bremelanotide exposure doubles in severe renal impairment, implying higher risk if extrapolated to MT‑II; organ impairment increases adverse event potential.
• Hepatic impairment: Use caution. Limited data exist on severe hepatic disease for the class; labeling recommends caution.
• Pregnancy and lactation: Avoid or use with caution. Human safety data are insufficient for the class; labeling advises against use.
• Dermatologic risk/monitoring (atypical nevi, melanoma history): Exercise caution and monitor. Class reports include hyperpigmentation and nevi changes; bremelanotide reports focal hyperpigmentation, and MT‑II/related melanocortins act on MC1R to drive melanogenesis.

Known and theoretical drug interactions

• Delayed gastric emptying (kinetic interaction): Class data show slowed gastric emptying with bremelanotide that reduced exposure to some oral drugs (e.g., naltrexone, indomethacin). Anticipate altered absorption/time to effect for time‑dependent oral medications with MT‑II. No significant interaction with many other orals in testing; minimal CYP involvement is expected.
• Ethanol: No clinically significant interaction was detected with bremelanotide; extrapolation suggests low likelihood of a direct MT‑II–ethanol interaction, though CNS effects can still overlap.
• PDE5 inhibitors (sildenafil/tadalafil/vardenafil): Theoretical pharmacodynamic interaction. Central MC4R agonism enhances erection; combining with peripheral NO/cGMP enhancers may increase priapism risk.
• Sympathomimetics or BP‑raising agents (e.g., decongestants, stimulants): Theoretical additive pressor/tachycardia effects. MT‑II increases BP/HR through MC3/4‑mediated sympathetic pathways; additive effects are plausible. (rinneUnknownyearnewperspectiveson pages 51-53)
• Beta‑blockers/antihypertensives: Potential modifying interaction. In animals, metoprolol abolished the MT‑II‑induced pressor response, indicating adrenergic involvement; clinical significance in humans is uncertain. (rinneUnknownyearnewperspectiveson pages 51-53)
• Opioids/analgesics: Theoretical interaction on analgesia/reward. MC4R signaling modulates opioid pathways and morphine antinociception; MT‑II may alter opioid efficacy or withdrawal‑related behaviors.
• Myotoxic drugs (e.g., statins, fibrates, daptomycin): Theoretical additive myotoxicity risk. MT‑II has been linked to systemic toxicity including rhabdomyolysis in case literature; combining with known myotoxins could raise risk.

Mechanistic context

• MT‑II is a nonselective melanocortin agonist with activity at MC1R, MC3R, MC4R, and MC5R. Hemodynamic changes are primarily mediated by MC3/MC4 pathways and sympathetic activation; pro‑erectile effects are MC4R‑mediated; melanogenesis and focal hyperpigmentation arise via MC1R activation. These receptor‑level data support the contraindications and theoretical interactions enumerated above.

Evidence limits

• Melanotan‑2 is not an approved medicine; direct high‑quality clinical pharmacology data are limited. Where direct MT‑II data are lacking, we extrapolated from the closely related approved agent bremelanotide (PT‑141) and from mechanistic literature; such extrapolations should be treated as theoretical until directly tested.

Contraindications#

Objective status: All objectives completed. We synthesized known and theoretical contraindications and drug–drug interactions for Melanotan‑2 (MT‑II), drawing on direct MT‑II case evidence, mechanistic melanocortin receptor data, and class analog findings from bremelanotide (PT‑141).

Toxicology#

We searched the available literature for Melanotan II (MT‑II) toxicology endpoints but retrieved only limited, human case‑level evidence suitable for citation. No primary preclinical LD50, organ histopathology, or genotoxicity datasets were found in the accessible texts. Key findings from the available source are summarized below and in the embedded table.

Overall summary

• LD50: Not located in the retrieved evidence. No species‑specific lethal dose values could be confirmed from accessible sources identified by our search.
• Organ toxicity and notable clinical adverse events: A peer‑reviewed case report documents ischemic (low‑flow) priapism after a single subcutaneous MT‑II dose of approximately 2 mg. The same report notes commonly observed adverse effects in human use (nausea, fatigue, flushing, dizziness, yawning) and references an external case of systemic toxicity with rhabdomyolysis. Product quality and dosing variability in unregulated MT‑II are emphasized.
• Cardiovascular signals: The case‑level source highlights concerns about blood pressure increases reported for a related melanocortin agonist (bremelanotide), suggesting possible class‑related cardiovascular effects, though direct controlled MT‑II hemodynamic data were not available in the retrieved evidence.
• Mutagenicity/genotoxicity: No Ames test, micronucleus, chromosomal aberration, or other genotoxicity data for MT‑II were located in the retrieved evidence.
• Dose–response relationships: Controlled dose–response metrics (including NOAEL/LOAEL) were not reported in the retrieved evidence. The case report indicates adverse events at an estimated 2 mg SC in one patient but cannot establish population‑level dose–response.

Interpretation

• The clinical case evidence indicates that serious adverse events such as ischemic priapism can occur after subcutaneous administration of MT‑II, alongside frequently described transient effects (nausea, flushing, yawning). Cardiovascular liability is plausible by class inference; however, direct MT‑II controlled hemodynamic data are lacking in the retrieved texts.
• Critical toxicology domains remain uncharacterized in the retrievable literature set: animal LD50, target‑organ histopathology, and mutagenicity/genotoxicity testing. As a result, NOAEL/LOAEL and quantitative dose‑response relationships cannot be defined from the current evidence.

Limitations and next steps

• The accessible evidence is restricted to a single citable case‑level source; broader preclinical toxicology (acute, subacute, chronic, reproductive, and genetic toxicology) for MT‑II may exist but was not retrievable within the current tool results. Additional database access (e.g., proprietary toxicology dossiers, regulatory filings, or broader indexing of older pharmacology reports) would be needed to obtain LD50 values, organ histopathology, and formal genotoxicity outcomes.

Evidence Gaps#

• Human adverse event data is limited to anecdotal reports
• Systematic adverse event monitoring has not been conducted
• Drug interaction studies are incomplete
• Long-term safety profiles are unknown

Related Reading#

• Melanotan-2 overview and research guide
• Melanotan-2 dosing protocols
• Melanotan-2 risks and legal status